

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

Pathophysiology and immunomodulation associated with *Haemonchus contortus* infection

**A dissertation presented in partial fulfilment of the requirements
for the degree of**

DOCTOR OF PHILOSOPHY

at Massey University, Palmerston North, New Zealand

Zia-ur-Rehman

2015



*In the Name of Allah the Most
Gracious, the Most Merciful.*

Table of Contents

Table of Contents	i
Abstract	x
Acknowledgements	xii
List of Figures.....	xiv
List of Tables	xxii
List of Abbreviations	xxiii
Introduction.....	xxx
 CHAPTER 1 LITERATURE REVIEW	 1
1.1. LIFE CYCLE OF ABOMASAL NEMATODES.....	1
1.2. PATHOPHYSIOLOGY OF ABOMASAL PARASITISM	2
1.2.1. Parietal cell loss and hypoacidity	3
1.2.2. Hypergastrinaemia.....	6
1.2.3. Hyperpepsinogenaemia	7
1.3. GASTRIC MUCOSAL BARRIER.....	9
1.3.1. Mucus.....	9
1.3.2. Epithelial cell integrity and permeability	11
1.3.3. Tight junctions	11
1.3.3.1. Molecular structure of tight junctions	12
1.3.3.2. Permeability of tight junctions	12
1.3.3.3. Pathology associated with tight junctions.....	14
1.3.3.4. Parasitic infections	15
1.4. IMMUNE RESPONSE TO HELMINTHS	17
1.4.1. Host factors	17
1.4.2. T _H 2 immune response	19
1.4.2.1. Innate response.....	19
1.4.2.2. Adaptive immunity	23
1.4.3. Dendritic cells	23
1.4.3.1. Origins and subsets.....	24

1.4.3.2. Antigen presentation and DC maturation	24
1.4.4. Antibody production in lymph nodes	26
1.5. HELMINTH IMMUNOMODULATION	27
1.5.1. Ruminant gastrointestinal parasites	28
1.5.1.1. Host mimics.....	29
1.5.1.2. Complement inhibition	29
1.5.1.3. Lymphocyte proliferation	29
1.5.1.4. Dendritic cells	31
1.6. CONCLUSIONS	32
 CHAPTER 2 EFFECTS OF <i>H. CONTORTUS</i> ES PRODUCTS ON EPITHELIAL CELL PERMEABILITY	 33
2.1. INTRODUCTION	33
2.1.1. Initiation of host pathology	33
2.1.2. Epithelial cell tight junctions	33
2.1.3. Effect of pathogens on tight junctions	34
2.1.4. Host recognition of mediators	35
2.1.5. Enolase	36
2.2. MATERIALS AND METHODS	38
2.2.1. Preparation of adult <i>H. contortus</i> ES Products.....	38
2.2.1.1. Maintenance of <i>H. contortus</i> cultures	38
2.2.1.2. Collection of adult worms.....	38
2.2.1.3. Preparation of adult <i>H. contortus</i> ES products	39
2.2.1.4. Estimation of lipo-polysaccharide (LPS) content.....	39
2.2.2. Expression of adult <i>H. contortus</i> enolase in <i>E. coli</i>	39
2.2.2.1. Extraction of RNA from adult <i>H. contortus</i>	39
2.2.2.2. cDNA synthesis	40
2.2.2.3. Cloning of <i>H. contortus</i> enolase into the AY2.4 vector	40
2.2.2.3.1. Amplification of <i>H. contortus</i> enolase cDNA	40
2.2.2.3.2. Isolation of the AY2.4 vector.....	41
2.2.2.3.3. Restriction enzyme digestion of enolase cDNA PCR product and AY2.4 vector	41
2.2.2.3.4. Ligation of vector (AY2.4) and insert (<i>H. contortus</i> enolase)..	42

2.2.2.4. Transformation of <i>E. coli</i> Top-10 competent cells with vector:insert	42
2.2.2.5. Analysis of transformants	43
2.2.2.6. Transformation of chemically-competent BL21 Star (DE3)	43
2.2.2.7. Optimisation of expression of recombinant <i>H. contortus</i> enolase (rHcENO)	44
2.2.2.8. Assessment of protein expression	44
2.2.2.9. Expression of rHcENO	45
2.2.2.10. Preparation of bacterial cell lysate under native conditions.....	45
2.2.2.11. Purification under native conditions	46
2.2.2.12. Dialysis	46
2.2.2.13. Protein estimation.....	46
2.2.2.14. Probing western blot for His-tagged proteins	46
2.2.2.15. rHcENO activity (E.C. 4.2.1.11)	47
2.2.3. Expression of recombinant adult <i>H. contortus</i> arginine kinase (rHcAK)	47
2.2.4. Production of negative control for recombinant enzymes	48
2.2.5. Panning with HcES and rHcENO of an ovine single chain antibody library displayed on phage	48
2.2.6. RGM1 cell monolayers	48
2.2.7. Caco-2 cell monolayers	49
2.2.8. Incubation of Caco-2 monolayers with <i>H. contortus</i> products.....	50
2.2.8.1. <i>H. contortus</i> ES products.....	50
2.2.8.2. Recombinant <i>H. contortus</i> enolase (rHcENO) and arginine kinase (rHcAK)	50
2.2.8.3. Incubation of single chain antibodies displayed on bacteriophage with <i>H. contortus</i> ES products	50
2.2.8.4. Incubation of single chain antibodies displayed on bacteriophage with rHcENO	51
2.2.9. Immunochemical staining of tight junction proteins	51
2.2.10. Data analysis	52
2.3. RESULTS	53
2.3.1. rHcENO gene sequence	53
2.3.2. Recombinant enzyme expression	53
2.3.3. Effect of <i>H. contortus</i> ES products on Caco-2 cell monolayer TEER	53

2.3.4. Interaction of single chain antibodies displayed on bacteriophage with <i>H. contortus</i> ES products	54
2.3.5. Effects of rHcENO and rHcAK on Caco-2 cell monolayer TEER....	54
2.3.6. Interaction of single chain antibodies displayed on bacteriophage with recombinant <i>H. contortus</i> enolase	55
2.3.7. Effect of <i>H. contortus</i> ES products on ZO-1 and occludin	55
2.4. DISCUSSION	55
2.4.1. Epithelial cell models	56
2.4.2. <i>H. contortus</i> ES increased permeability	57
2.4.3. Host recognition of component(s) of ES products	58
2.4.4. Permeabilising component of ES products	59
2.4.4.1. Production of recombinant <i>H. contortus</i> enolase (rHcENO).....	60
2.4.4.2. rHcENO reduced Caco-2 cell monolayer TEER.....	60
2.4.5. Host recognition of rHcENO.....	61
2.4.6. Conclusions	62
 CHAPTER 3 IMMUNOMODULATION OF HUMAN MONOCYTE DERIVED DENDRITIC CELLS BY <i>H. CONTORTUS</i> ES PRODUCTS	64
3.1. INTRODUCTION	64
3.1.1. Immune response to helminths.....	64
3.1.2. Immunomodulation of dendritic cells.....	65
3.1.3. <i>In vitro</i> dendritic cell model	66
3.1.3.1. Surface expressed molecules.....	66
3.1.3.1.1. Antigen presentation	67
3.1.3.1.2. Co-stimulatory molecules	67
3.1.3.1.3. Regulatory molecules.....	68
3.1.3.2. Cytokines and chemokines.....	69
3.2. MATERIALS AND METHODS	73
3.2.1. Generation of human monocyte derived dendritic cells (mdDCs)...	73
3.2.2. Generation of sheep mdDCs	74
3.2.3. Experimental overview.....	75
3.2.4. Expression of mdDC surface markers and secreted cytokines/chemokines	75
3.2.4.1. Test substances	76
3.2.5. Staining for surface antigens	77

3.2.6. Staining for total cellular galectin-1	77
3.2.7. Flow cytometry for surface antigens and total galectin-1.....	78
3.2.8. Cytokine assay	79
3.2.9. CarLA uptake assay	80
3.2.10. Statistical analysis	80
3.3. RESULTS	81
3.3.1. Effect of ES products on expression of cell surface molecules	81
3.3.1.1. Non-stimulated mdDCs	81
3.3.1.2. ES-stimulated mdDCs	82
3.3.1.3. Galectin-1 expression by ES-stimulated mdDCs	82
3.3.2. Effect of CarLA on expression of cell surface molecules.....	83
3.3.3. CarLA uptake.....	83
3.3.4. Effect of LPS or OVA on expression of cell surface molecules	84
3.3.5. Effect of LPS and ES product co-stimulation on expression of cell surface molecules	85
3.3.6. Effect of ES products on secretion of chemokines and cytokines...	85
3.3.6.1. Non-stimulated mdDCs	86
3.3.6.2. ES-stimulated mdDCs	86
3.3.7. Effect of LPS on secretion of chemokines and cytokines	86
3.3.8. Effect of LPS and ES products co-stimulation on secretion of chemokines and cytokines.....	87
3.3.8.1. ES products reduced the response to LPS	87
3.3.8.2. ES products increased the response to LPS	88
3.3.8.3. ES products did not change the response to LPS.....	88
3.4. DISCUSSION	88
3.4.1. Dendritic cell model	89
3.4.2. Effect of ES products on DC surface molecules and cytokine secretion.....	90
3.4.2.1. Antigen presentation.....	91
3.4.2.2. Co-stimulatory molecules	92
3.4.2.3. Regulatory molecules	93
3.4.2.4. Cytokines and chemokines.....	94
3.4.3. Immunomodulation by ES products of the response to LPS	96
3.4.3.1. Exposure to LPS	96
3.4.3.2. Co-stimulation with ES products and LPS	97

3.4.4. Individual donor responses	98
---	----

CHAPTER 4 <i>In vitro</i> proliferation of lymph node cells from sheep infected with <i>H. contortus</i>	102
4.1. INTRODUCTION	102
4.1.1. Immune response to helminths	102
4.1.2. Lymph nodes	103
4.1.3. Antibody production in lymph nodes	104
4.1.4. Immunosuppression of lymphocytes	105
4.1.5. <i>In vitro</i> lymphocyte proliferation assays	105
4.1.6. Mitogen-induced lymphocyte proliferation	106
4.2. MATERIALS AND METHODS	108
4.2.1. Experimental overview	108
4.2.2. Vaccination Trial #1	108
4.2.3. Vaccination Trial #2	109
4.2.4. Culture of lymph node cells	109
4.2.5. Stimulation with ES products or ConA	110
4.2.6. Stimulation index	111
4.2.7. IFN- γ and IL-4 assays	111
4.2.7.1. IFN- γ	111
4.2.7.2. IL-4 assay	112
4.2.8. Statistical analysis	112
4.3. RESULTS	113
4.3.1. Vaccination Trial #1	113
4.3.1.1. Cell proliferation	113
4.3.1.2. Parasitology	113
4.3.2. Vaccination Trial #2	114
4.3.2.1. Cell proliferation	114
4.3.2.2. Parasitology	114
4.3.3. IFN- γ and IL-4	115
4.4. DISCUSSION	115
4.4.1. Lymphocyte pool	115
4.4.2. T cell receptor	117
4.4.3. Stimulation of lymphocyte proliferation by ConA	117

4.4.4. Proliferative response to <i>H. contortus</i> ES products	119
CHAPTER 5 GENERAL DISCUSSION	122
5.1. MUCOSAL PERMEABILITY	123
5.2. IMMUNOSUPPRESSION IN <i>H. CONTORTUS</i> INFECTED SHEEP	126
5.3. IMMUNOMODULATION BY <i>H. CONTORTUS</i> ES PRODUCTS	127
5.4. VACCINES INCORPORATING PARASITE SECRETIONS	129
5.5. HUMAN THERAPIES USING PARASITE SECRETIONS OR PRODUCTS	132
5.6. FUTURE WORK	134
References	135
Appendix 1: Parasitology	183
1.1. Faecal egg flotation	183
1.2. Faecal egg count	183
1.3. Larval culture stock	183
1.4. Recovery of adult worms	185
1.5. RP2 medium for collecting ES products	186
Appendix 2: Molecular Biology	187
2.1. cDNA synthesis	187
2.2. Media	187
2.2.1. Luria broth (LB)	187
2.2.2. LB Agar	188
2.2.3. Yeast extract and tryptone (YT) (2X)	188
2.3. Solutions	188

2.3.1. 5X Native purification buffer.....	188
2.3.2. 1X Native purification buffer.....	188
2.3.3. 3M Native imidazole	188
2.3.4. Native binding buffer containing imidazole.....	189
2.3.5. Dialysis buffer (10x PBS).....	190
2.3.6. 2X SDS-PAGE sample buffer	190
2.3.7. Reagents used in western blotting	190
 Appendix 3: Cell culture.....	 192
3.1. Cell culture media	192
3.1.1. Cell culture medium for RGM1 cells.....	192
3.1.2. Cell culture medium for Caco-2 cells	192
3.2. Cell passage	193
3.2.1. RGM1 cell passage	193
3.2.2. Caco-2 cell passage	193
3.3. Cryopreservation of cells.....	193
3.4. Thawing of cryopreserved cells	194
 Appendix 4: Immunohistochemistry	 195
4.1. Paraformaldehyde (PFA) 4%.....	195
4.2. Blocking buffer	195
4.3. Primary and secondary antibodies	195
 Appendix 5: Immunology	 197
5.1. Staining for surface antigens.....	197
5.2. Intracellular and surface staining for galectin-1	198
5.3. Cytokine assay.....	199

5.3.1. Prepration of reagents and samples	199
5.3.2. Staining proceedure.....	200
Appendix 6: Cell proliferation assay.....	201
6.1. Cell harvesting	201
6.2. Reagents and solutions.....	202
6.2.1. ELISA buffer	202
6.2.2. TMB buffer.....	202
6.2.3. TMB substrate	202
6.2.4. PBS-EDTA	203
Appendix 7: Statistical analysis.....	204
7.1. Experiment 1: effects of ES on mdDC surface markers.....	204
7.2. Experiment2: Effects of ES and LPS on mdDC surface markers.....	206
7.3. Experiment 2: Effects of ES and LPS on mdDC cytokine/chemokines...	212
7.4. Lymphocyte proliferation Trial 1	220

ABSTRACT

The aim of this project was to investigate host-parasite interactions, which might lead to alternate strategies to control the sheep abomasal nematode *Haemonchus contortus*. The project focused on two aspects of host parasite interactions: the initiation of host pathology and suppression of host immune responses associated with the onset of infection.

Adult *H. contortus* ES products increased the permeability of Caco-2 cell monolayers and this increase could be blocked by single chain antibodies against ES products displayed on phage. Recombinant *H. contortus* enolase may be one of the active components of ES as it mimicked the action of ES products on Caco-2 cells.

This is the first study of immunomodulation by adult *H. contortus* ES products of the phenotypic and functional properties of human monocyte-derived dendritic cells (mdDCs). Incubation with ES products resulted in semi-maturation of mdDCs, with weak up-regulation of the co-stimulatory molecules CD40 and CD80 and increased surface expression of the tolerogenic markers CD32, CD305 and galectin-1. The highly variable responses of mdDCs of individual donors biased the group data, particularly in response to co-stimulation with ES products and LPS. This highlights genetic diversity in the immune system and possible difficulties in developing worm-based therapies.

The blastogenic activities of cells from lymph nodes collected from two groups of infected and vaccinated sheep were measured by ³H-thymidine uptake after exposure to ConA or ES products. The Stimulation Index (SI) with ConA was 10-fold higher in cells from the older animals. Cells only from younger infected sheep had a reduced

response to ConA and vaccinated groups with reduced parasite burdens had the highest SI. There was little response to ES products in older sheep, but in younger animals there was a trend for lymphocyte SI to be greater with 10% ES in sheep with the fewest parasites.

These experiments show that *H. contortus* ES products may facilitate the initiation of host pathology and the potential to modulate responses of dendritic and lymph node cells during parasitism. Further identification of the specific ES components responsible may allow disruption of their actions, resulting in resilient and immune sheep.

ACKNOWLEDGEMENTS

First and foremost, I thank Allah Almighty for giving me courage, strength, health and perseverance for the successful completion of my PhD.

I wish to thank the Institute of Veterinary, Animal and Biomedical Sciences and the Hopkirk Research Institute, AgResearch Limited for allowing me to use their facilities and for their administrative support throughout my Ph.D. I am also indebted to the former for research and travel grants which enabled the research work to be undertaken and gave me opportunity to present my work at various conferences in New Zealand and Australia.

I would like to thank my supervisors for guidance, patience and encouragement in helping me to achieve this goal. I would particularly express my sincere thanks to my chief supervisor Prof. Heather Simpson; it would not have been possible to write this doctoral dissertation without her excellent guidance, enthusiasm, helpful criticism, moral boost and timely advice. I am grateful to her, whose patience I stretched on occasions to its absolute maximum. Heather, many thanks for having me as a doctoral student and for your good nature, support and encouragement throughout my studies.

To Dr Tony Pernthaner, I am very grateful for your inspiration, guidance, timely feedback and being always available to help, particularly for your continuous support and introducing me to the monster of immunology. My sincere thanks to Dr Jacqui Knight for her continuous support and prompt feedback, without which completion of this dissertation would not have been possible. Special thanks for Dr Bruce Simpson for his patience and encouragement throughout my studies.

I would like to thank the scientists and technical staff at both the Hopkirk Research Institute and Massey University for their help in my project. Qing Deng is thanked for panning the antibody libraries and help with cell culture, Joanna Roberts for helping me with flow cytometry, Dr Saleh Umair for providing arginine kinase, Dr Matthew Savoian, Niki Murray and Jordan Taylor for their help with microscopy, Michael Hogan for help in the post-mortem room, Evelyn Lupton, Saritha Gils and Dr Matthew Perrot for their help in histology and Roy Meeking for allowing me to use the facilities at the Hopkirk Research Institute. Dr John Koolaard is thanked for statistical analyses. My thanks to all Hopkirk staff for being supportive, cheerful and always available for help with a smile.

The dream of a PhD in New Zealand would never have been fulfilled without unflinching support from my family. They not only supported me financially but also provided me with huge moral boosts. To my family, though only my name appears on the cover of this dissertation, you have a great contribution to its production; thank you for being there, for your encouragement and support. Mom! Very special thanks for your countless prayers. I would like to thank my wife, sisters and brothers for their patience and supporting me every step on the way in the ways they all have done.

Finally, I would like to show my gratitude and acknowledge my friends for their support and encouragement, especially Asad Razzaq, Muhammad Umar Khan, Mian Muhammad Atif, Dr Muhammad Shuaib, Morag Cunningham, Paul Stock, Tanushree Gupta, Neha Jha, Gajen Sinnathamby and many more who have been a direct influence on me and without whom this process would have been very difficult.

Thank you all for your help and support during the ups and downs.

Zia

List of Figures

	Facing page
Chapter 1	
Fig. 1.1. Cell-cell junctions..	11
Fig. 1.2. Structure of tight junctions, showing kissing points.	11
Fig. 1.3. The integral proteins claudins, occludins and junctional adhesion molecules (JAMs) and the peripheral zonula occludin (ZO) proteins link the tight junction and actin cytoskeleton	12
Fig. 1.4. Model of a tight junction, showing the transmembrane proteins occludin, claudins and JAM and the tight junction plaque proteins, which have scaffolding as well as regulatory functions.....	12
Fig. 1.5. An overview of functions of innate effector cells during the T _H 2 immune response to helminths.....	19
Fig. 1.6. Cells and cytokines involved in immune responses in infection with <i>Nippostrongylus brasiliensis</i>	21
Fig. 1.7. Cytokines released by cells of the innate immune system after exposure of APCs to helminths.	22
Fig. 1.8. Comparison of generation and activation of classical macrophages (M1) and alternatively activated macrophages (M2).. .	22
Fig. 1.9. Gamma delta T cell activation.	23

Fig. 1.10. Ontogeny of dendritic cell subsets.....	23
---	----

Fig. 1.11. Subsets of dendritic cells in mouse and human, showing transcription factor requirements and effects on T cells.	24
---	----

Fig. 1.12. Helminth induced immunomodulation by ES products (bold) and known molecules.	28
---	----

Chapter 2.....

Fig. 2.1. Adult <i>H. contortus</i> on the mucosal surface of the parasitised sheep abomasum.....	38
--	----

Fig. 2.2. Formation of clumps of adult <i>H. contortus</i> worms during incubation in RP2 culture medium.....	39
--	----

Fig. 2.3. Transwell® system.....	49
---	----

Fig. 2.4. Apparatus for measurement of transepithelial electrical resistance (TEER) of cultured cells.	49
--	----

Fig. 2.5. Alignment of <i>H. contortus</i> enolase #1 protein sequence (Genbank Accession No. KM502544) with <i>H. contortus</i> enolase #2 (ADK47524) and enolases from <i>Anisakis simplex</i> (Q8MU59), <i>Brugia malayi</i> (A8PFE3), <i>Onchocerca volvulus</i> (Q7YZX3), <i>Trichinella spiralis</i> (Q967U0), <i>Schistosoma bovis</i> (B2LXU1), <i>Schistosoma japonicum</i> (P33676), <i>Schistosoma mansoni</i> (Q27877), <i>Echinostoma caproni</i> (CAR47551), <i>Fasciola hepatica</i> (Q27655), <i>Echinococcus granulosus</i> (D0VLV3), <i>Taenia asiatica</i> (C9V487), and <i>Streptococcus pneumonia</i> (CAC8309).....	53
--	----

Fig. 2.6. SDS-PAGE of recombinant <i>H. contortus</i> enolase..	53
Fig. 2.7. Effects of exposure of Caco-2 cell monolayers to different culture media on the trans-epithelial resistance (TEER) (mean \pm S.E.M) normalised to zero time..	53
Fig. 2.8. Effects of exposure to <i>H. contortus</i> ES products (●) and control medium (▲) on the trans-epithelial resistance (TEER) (mean \pm S.E.M, $n = 16$), normalised to zero time, of Caco-2 cell monolayers..	54
Fig. 2.9. Inhibition with phage displaying anti- <i>HcES</i> single chain antibodies of the effects of <i>HcES</i> on the trans-epithelial resistance (TEER) of Caco-2 monolayers.....	54
Fig. 2.10. Effects of phage displaying anti- <i>HcES</i> scFvs on the trans-epithelial resistance (TEER) of Caco-2 monolayers..	54
Fig. 2.11. Effects of phage displaying unselected scFvs combined with <i>HcES</i> on the trans-epithelial resistance (TEER) of Caco-2 monolayers..	54
Fig. 2.12. Effects of phage displaying anti- <i>rHcENO</i> scFvs combined with <i>HcES</i> on the trans-epithelial resistance (TEER) of Caco-2 monolayers.	54
Fig. 2.13. Effects of exposure to recombinant <i>H. contortus</i> enzymes on the trans-epithelial resistance (TEER) (mean \pm S.E.M) of Caco-2 monolayers normalised to zero time.....	54

Fig. 2.14. Inhibition of phage displaying unselected single chain scFvs of the effects of rHcENO on the trans-epithelial resistance (TEER) of Caco-2 monolayers.. 55

Fig. 2.15. Effects of phage displaying anti-rHcENO scFvs combined with rHcENO on the trans-epithelial resistance (TEER) of Caco-2 monolayers..... 55

Fig. 2.16. Effects of phage displaying anti-HcES scFvs combined with rHcENO on the trans-epithelial resistance (TEER) of Caco-2 monolayers..... 55

Fig. 2.17. Effect of exposure to *H. contortus* ES products (right) or control medium (left) on the location of ZO-1 in the tight junctions of Caco-2 cell monolayers..... 55

Chapter 3.....

Fig. 3.1. Normalised expressions of surface CD32, CD305 and CD40 of mdDCs exposed to 0 - 10% HcES products.. 82

Fig. 3.2. Normalised expressions of surface HLA-DR, CD80 and CD86 of mdDCs exposed to 0 - 10% HcES products..... 82

Fig. 3.3. Normalised expressions of surface CD32, CD305, CD40 and HLA-DR of mdDCs exposed to 0 - 10% HcES products..... 82

Fig. 3.4. Normalised expressions of surface CD80, CD86 and CD83 of mdDCs exposed to 0 - 10% HcES products..... 82

Fig. 3.5. Normalised expressions of surface galectin-1 of mdDCs exposed to 0 - 10% *HcES* products..... 82

Fig. 3.6. Normalised expressions of cellular (Surface and intracellular) galectin-1 of mdDCs exposed to 0 - 10% *HcES* products..... 82

Fig. 3.7. Expressions (median fluorescence intensity (MFI)) (mean \pm SEM; $n = 8$) of surface CD305, CD32, CD80, CD86, HLA-DR and CD40 of mdDCs either non-stimulated (NS) or exposed to 10 μ g/ml of *T. colubriformis* CarLA..... 83

Fig. 3.8. CarLA uptake (median fluorescence intensity (MFI)) by mdDCs of individual donors from medium containing 0 - 100 μ g/ml of *T. colubriformis* CarLA 83

Fig. 3.9. Normalised expressions (mean \pm SEM; $n = 8$) of surface CD80, CD86, CD40, HLA-DR, CD305 and CD32 by mdDCs exposed to 100ng/ml LPS or 10 μ g/ml ovalbumin (OVA)..... 84

Fig. 3.10. Normalised expressions of surface CD80, CD86, CD40, HLA-DR, CD305 and CD32 by individual donor mdDCs exposed to 100ng/ml LPS or 10 μ g/ml ovalbumin (OVA)..... 84

Fig. 3.11. Normalised expressions of surface CD80, CD83, CD86 and CD40 of mdDCs exposed to 0 - 30ng/ml of LPS. 84

Fig. 3.12. Normalised expressions of surface CD32, CD305 and HLA-DR of mdDCs exposed to 0 - 30ng/ml of LPS. 84

- Fig. 3.13.** Normalised expressions of surface CD80, CD40 and HLA-DR of mdDCs co-exposed to 0-10% *HcES* products and 0 - 30ng/ml of LPS..... 85
- Fig. 3.14.** Normalised expressions of surface CD32, CD305 and CD83 of mdDCs co-exposed to 0 - 10% *HcES* products and 0 - 30ng/ml of LPS..... 85
- Fig. 3.15.** Normalised expressions of surface CD86 of mdDCs co-exposed to 0 - 10% *HcES* products and 0-30ng/ml of LPS.. 85
- Fig. 3.16.** Normalised secretion of IFN- γ , MCP-1 and MIP-1 β of mdDCs exposed to 0 - 10% *HcES* products..... 86
- Fig. 3.17.** Normalised secretion of MIP-1 α , IL-8 and ICAM-1 of mdDCs exposed to 0 - 10% *HcES* products..... 86
- Fig. 3.18.** Normalised secretion IL-10, IP-10, MCP-1 and E-selectin by mdDCs exposed to 0 - 30ng/ml of LPS. 86
- Fig. 3.19.** Normalised secretion of IFN- γ , ICAM-1, IFN- α and IL-17A by mdDCs exposed to 0 - 30ng/ml of LPS. 86
- Fig. 3.20.** Normalised secretion of MIP-1 α , IL-6 and IL-8 by by mdDCs exposed to 0 - 30ng/ml of LPS. 86
- Fig. 3.21.** Normalised secretion of IL-10, IP-10 and TNF- α by mdDCs exposed to 0 - 10% *HcES* products and 0 - 30ng/ml of LPS. 87

Fig. 3.22. Normalised secretion of MIP-1 α , IL-8 and IL-6 by mdDCs exposed to 0 - 10% *HcES* products and 0 - 30ng/ml of LPS. 88

Fig. 3.23. Normalised secretion of IFN- γ , ICAM-1 and MCP-1 by mdDCs exposed to 0 - 10% *HcES* products and 0 - 30ng/ml of LPS. 88

Fig. 3.24. Normalised secretion of E-selectin, IL-17A and IFN- α by mdDCs exposed to 0 - 10% *HcES* products and 0 - 30ng/ml of LPS. 88

Fig. 3.25. Normalised secretion of MIP-1 β , IL-13 and IL-12p70 by mdDCs cexposed to 0 - 10% *HcES* products and 0 - 30ng/ml of LPS.88

Chapter 4.....

Fig. 4.1. Lymph node structure..... 103

Fig. 4.2. Effect of ConA on the Stimulation Index (SI) (mean \pm SEM) of cells from abomasal lymph nodes of sheep in vaccination trial #1.. . 113

Fig. 4.3. Effect of 0 - 10% *H. contortus* ES products on the Stimulation Index (SI) (mean \pm SEM) of cells from abomasal lymph nodes of sheep in vaccination trial #1. 113

Fig. 4.4. Worm counts (mean \pm SEM) of sheep in vaccination trial #1.113

Fig. 4.5. Cumulative FEC (mean \pm SEM) for Weeks 3 - 8, 3 - 5, 6 - 8 and the final week of sheep in vaccination trial #1..... 113

Fig. 4.6. Effect of ConA on the Stimulation Index (SI) (mean \pm SEM) of cells from abomasal lymph nodes of sheep in vaccination trial #2. .. 114

Fig. 4.7. Effect of 0 - 10% *H. contortus* ES products on the Stimulation Index (SI) (mean \pm SEM) of cells from abomasal lymph nodes of sheep in vaccination trial #2. 114

Fig. 4.8. Worm counts (mean \pm SEM) of sheep in vaccination trial #2...
..... 114

Fig. 4.9. Cumulative FEC (mean \pm SEM) for Weeks 2 - 11, 2 - 7, 8 - 11 and the final week of sheep in vaccination trial #2..... 114

Fig. 4.10. Standard curves for the cytokine assays..... 115

List of Tables

Facing page

Chapter 1	
Table 1.1 Immunomodulators identified from helminth parasites of mammals.	28
Chapter 3	
Table 3.1 Antibodies to surface antigens on mdDCs in panels A and B, showing fluorochromes, clones and final concentrations.....	77
Table 3.2 Expressions of surface markers (median fluorescence intensity (MFI)) in non-stimulated mdDCs of Donors 1-6 (Expt #1)	81
Table 3.3 Expressions of surface markers (median fluorescence intensity (MFI)) in non-stimulated mdDCs of Donors 1, 2, 4 and 7 (Expt #2).	81
Table 3.4 Effect of CarLA on expressions of surface markers (mean fluorescence intensity (MFI)) by mdDCs of Donors 1-6.	83
Table 3.5 Upper and lower detectable limits of cytokines and chemokines.	85
Table 3.6 Secretion of cytokines and chemokines by non-stimulated mdDCs of Donors 1, 2, 4 and 7..	86

List of Abbreviations

AAMs	alternatively activated macrophages
Ab	antibody
ADCC	antibody dependent cellular cytotoxicity
ADJ	adjuvant
ADP	adenosine diphosphate
AEC	3-Amino-9-ethylcarbazole
AJ	adherens junctions
AK	arginine kinase
<i>A. lumbricoides</i>	<i>Ascaris lumbricoides</i>
AMcase	acidic mammalian chitinase
Amot	angiomin
ANOVA	analysis of variance
APC	antigen presenting cell
aPKC	atypical protein kinase C
ASIP	aPKC isotype-specific interacting protein
ASP	<i>Ancylostoma</i> secreted proteins
B cells	B lymphocytes
BES	<i>Brugia malayi</i> ES
<i>B. malayi</i>	<i>Brugia malayi</i>
bp	base pair
BRSV	bovine respiratory syncytial virus
BSA	bovine serum albumin
CAR	coxsackievirus and adenovirus receptor
CarLA	Carbohydrate larval antigen
CCR7	chemokine (C-C motif) receptor 7
cDC	conventional dendritic cells
Cdc42	cell division control protein 42 homolog
cDNA	complementary deoxyribonucleic acid
CDP	common DC progenitor

CHaFFs	chitinase and FIZZ family members CMP
	common myeloid progenitor
CIP4	Cdc42- interacting protein 4
CLA	cutaneous lymphocyte-associated antigen
CLR	C-type lectin receptors
ConA	concanavalin A
CPI	cysteine proteinase inhibitor (cystatin)
CTGF	connective tissue growth factor
Cy	cyanine
DC	dendritic cells
DC-SIGN	dendritic cell specific intercellular adhesion molecule-3-grabbing non-integrin
Der p 1	<i>Dermatophagoides pteronyssinus</i> allergen
DNA	deoxyribonucleic acid
DS	desmosome
EDN	eosinophil derived neurotoxin
ECL	enterochromaffin-like
<i>E. coli</i>	<i>Escherichia coli</i>
EGF	epidermal growth factor
<i>E. granulosus</i>	<i>Echinococcus granulosus</i>
ES	excretory secretory
ESGPs	eosinophil secondary granule proteins
ETP	early thymic progenitor
EU	endotoxin unit
FBS	foetal bovine serum
FEC	faecal egg count
<i>F. hepatica</i>	<i>Fasciola hepatica</i>
FITC	fluorescein isothiocyanate
FIZZ	found in inflammatory zone
FMOs	fluorescence minus one
g	gram
<i>g</i>	gravitational force
GAP	GTPase-activating protein

GAPDH	glyceraldehyde-3-phosphate
<i>G. duodenalis</i>	<i>Giardia duodenalis</i>
GM-CSF	granulocyte-macrophage colony-stimulating factor
GPCR	G protein-coupled receptor
GTP	guanosine triphosphate
h	hour
HcES	<i>Haemonchus contortus</i> excretory secretory products
<i>H. contortus</i>	<i>Haemonchus contortus</i>
HES	<i>Heligmosomoides polygyrus</i> ES
HLA-DR	human leukocyte antigen-DR
<i>H. polygyrus</i>	<i>Heligmosomoides polygyrus</i>
<i>H. pylori</i>	<i>Helicobacter pylori</i>
HRP	horse radish peroxidase
HSC	hematopoietic stem cell
ICAM-1	intracellular adhesion molecule-1
iDC	inflammatory dendritic cell
IFN	interferon
Ig	immunoglobulin
IL	interleukin
INF	infected
IP-10	IFN- γ -inducible protein-10
IPSE	IL-4-inducing principle pf schistosome eggs
JAM	junctional adhesion molecules
JEAP	angiomin-like-protein 1
kDa	kilodalton
KGF	keratinocyte growth factor
L	litre
L-NES	<i>N. brasiliensis</i> larval ES
LAIR-1	leucocyte-associated Ig-like receptor-1
LAP	latency-associated protein
LC	Langerhans cell
LDH	lysine dehydrogenase

LL	laminated layer
LPS	lipopolysaccharides
LSD	least significant difference
L1	first stage larva
L2	second stage larva
L3	third stage larva
L4	fourth stage larva
L5	fifth stage larva
M	molar
mAb	monoclonal antibody
MCP-1	monocyte chemo-attractant protein-1
mdDC	monocyte derived dendritic cell
MDP	macrophage DC progenitor
MFI	median fluorescence intensity
mg	milligram
MHC	major histocompatibility complex
MIF	macrophage migration inhibitory factor
min	minute
MIP	macrophage inflammatory protein
ml	millilitre
mM	millimolar
<i>M. marshalli</i>	<i>Marshallagia marshalli</i>
MMPs	matrix metalloproteinase
MNC	mucous neck cells
mRNA	messenger ribonucleic acid
MUC5AC	mucin 5AC
MUC6	mucin 6
MUPP	multi-PDZ domain protein
Mv	microvilli
<i>n</i>	number
<i>N. americanus</i>	<i>Necator americanus</i>
<i>N. brasiliensis</i>	<i>Nippostrongylus brasiliensis</i>
NAD ⁺	nicotinamide adenine dinucleotide
NADH	reduced nicotinamide adenine dinucleotide

NI	non-infected
Ng	nanogram
Ni-NTA	Nickel-nitrilotriacetic acid
NLR	NOD-like receptors
NOD-like	nucleotide-binding oligomerisation domain-like
NS	non-stimulated
<i>O. ostertagi</i>	<i>Ostertagia ostertagi</i>
<i>O. volvulus</i>	<i>Onchocerca volvulus</i>
OVA	ovalbumin
PAGE	polyacrelamide gel electrophoresis
PAMPs	pathogen-associated molecular patterns
PAR	partitioning defective protein
PBMC	peripheral blood mononuclear cells
PBS	phosphate buffer saline
PCR	polymerase chain reaction
PD-L	programme death ligand
PE	phycoerythrin
PerCP	peridinin chlorophyll
PFU	plaque forming units
pg	picogram
PHA	phytohaemagglutinin
p.i.	post-infection
PK	pyruvate kinase
pmol	picomole
PRRs	pathogen recognition receptors
Rac1	Ras-related C3 botulinum toxin substrate 1
RELM	resistin-like molecule
RGM1	rat gastric mucosal first
Rich1	Rho GAP interacting with CIP4 homologues
rHcAK	recombinant <i>Haemonchus contortus</i> arginine kinase
rHcENO	recombinant <i>Haemonchus contortus</i> enolase

RhoA	Ras homolog gene family, member A
RIG-1	retinoic acid-inducible gene-1
RNA	ribonucleic acid
RO	reverse osmosis
scFvs	single chain antibody fragments
SDS	sodium duodecyl sulphate
S.E.M	standard error mean
SI	stimulation index
Sm	<i>Schistosoma mansoni</i>
<i>S. mansoni</i>	<i>Schistosoma mansoni</i>
<i>S. venezuelensis</i>	<i>Strongyloides venezuelensis</i>
SMC	surface mucous cells
SPN	serine proteinase inhibitor (serpin)
TAE	tris-acetate-EDTA
TBS	tris-buffered saline
T cells	T lymphocytes
<i>T. circumcincta</i>	<i>Teladorsagia circumcincta</i>
TCR	T cell receptors
<i>T. crassiceps</i>	<i>Taenia crassiceps</i>
<i>T. cruzi</i>	<i>Trypanosoma cruzi</i>
TEER	transepithelial electrical resistance
TES	<i>T. canis</i> ES
TGF	transforming growth factor
T _H 0	naïve T cell
T _H 1	type 1 immune response
T _H 2	type 2 immune response
Tiam-1	T-lymphoma invasion and metastasis-inducing protein-1
TJ	tight junction
TLR	Toll-like receptors
TNF	tumour necrosis factor
T _{regs}	regulatory T cells
TSLP	thymic stromal lymphopoietin
<i>T. spiralis</i>	<i>Trichinella spiralis</i>

ZO	zonula occluding
ZAK	ZO-1 associated kinase
μCi	microcurie
μg	microgram
μl	microliter

INTRODUCTION

In pasture-based grazing systems, like those in New Zealand, gastrointestinal nematodes are major contributors to serious health and welfare issues and fiscal losses, because of low productivity and high treatment and control costs (Leathwick et al., 2001). Haemonchosis, caused by the blood-feeding abomasal nematode *Haemonchus contortus*, is one of the major constraints on small ruminant health and production in warmer areas worldwide and in some parts of New Zealand, because of its blood feeding (Rowe et al., 1988; Le Jambre, 1995). At present, control of gastrointestinal nematodes depends heavily on the use of chemical anthelmintics (Wolstenholme et al., 2004) and, where feasible, pasture management. Under intensive grazing conditions, however, clean pastures are not readily available and extensive use of anthelmintics has resulted in increasing resistance to these chemicals (Jackson, 1993; Waller et al., 1995; Borgsteede et al., 1997; Van Wyk et al., 1997). Moreover, there are concerns about drug residues in meat and the environment (Madsen et al., 1990; Lumaret, 1993).

Problems associated with chemical treatment of livestock can be addressed by developing immunologically-based methods for gastrointestinal nematode control, ideally vaccination (Newton and Munn, 1999). Vaccines would provide protection during the susceptible period between weaning and development of natural immunity and would most likely use antigens responsible for causing host pathophysiology or necessary for parasite survival. An additional target may be the parasite immunomodulators which suppress the host immune response (Maizels et al., 2004).

This project investigated two aspects of the host-parasite interaction which are hoped to provide targets for new therapies. The

first was how the parasite initiates host pathology, which appears to be chemically mediated by their excretory-secretory (ES) products. Worm products were tested on a Caco-2 cell model to investigate the possibility that *H. contortus* can modulate epithelial cell permeability to facilitate entry of worm chemicals into host tissues. The second objective was to investigate the ability of abomasal parasites to suppress host immunity, first by an *in vitro* study of the effects of *H. contortus* ES components on dendritic cells and secondly by examining the ability of lymphocytes collected from infected and vaccinated sheep to proliferate *in vitro* in response to mitogens.